Current landscape of immunotherapy in esophageal cancer: a literature review
Esophageal cancer treatment is undergoing a paradigm shift with the advent of immunotherapy, particularly programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors.
Background and Objective: Esophageal cancer has witnessed a significant shift in its epidemiology within the United States. Adenocarcinoma of the esophagus is now the fastest‑growing solid malignancy, surpassing esophageal squamous cell carcinoma (ESCC) in frequency. There has been a concentrated effort to establish new therapies for dealing with this malignancy including immunotherapy in conjunction with surgery and radiotherapy. Our objective is to provide a comprehensive review of the current therapeutic strategies for esophageal cancer, with a particular focus on the emerging role of immunotherapy in combination with surgery and radiotherapy, and its impact on treatment outcomes.
These therapies hold promise for both second‑line and first‑line settings, with evolving biomarkers guiding treatment decisions.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Esophageal Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Clinical Trials Update in Resectable Esophageal Cancer
- Advances in targeted therapy for esophageal cancer
- A review of esophageal cancer research: emerging trends, progress and perspectives
- An esophageal cancer clinical trial - ES3